Abstract

This review article is proposed to underline method for the development by reversed-phase highperformance
liquid chromatography (RP-HPLC) and validation of rivaroxaban in individual and
pharmaceutical dosage form. Rivaroxaban is an anti-clotting drug, acts on Factor Xa, and stops the blood
clot development. In this study, different types of RP-HPLC methods which are available at present
for the determination of rivaroxaban in tablets (Xarelto 10 mg) are studied. There are different types
of the methods described for the estimation of this drug such as RP-HPLC, ultra performance liquid
chromatography (UPLC), and ultraviolet. However, nowadays, RP-HPLC plays a key role in quantitative
determination of drug. The review is focused on HPLC method development that is previously used for
rivaroxaban. Literature study carried on RP-HPLC, high-performance thin-layer chromatography, and
UPLC methods of rivaroxaban. The center of study was to develop as well as validate a stable, economic,
and rapid. The RP-HPLC method for assessment of rivaroxaban in its bulk formulation. Here, a new
aspect for this method was developed which revealed high sensitivity and reproducibility. The developed
method by RP-HPLC was validated by guidelines of ICH.